

NCT02386800 Raw comparison:

Summary:
CHIA has 8 criteria while your personal folder has 19 criteria
Total found criteria: 0/8
Total not Found: 8/8
Total Extra: 11
This trial is INVALID



Nothing was Found



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Patient is currently enrolled in a Novartis OGD or GMA-sponsored or Incyte-sponsored clinical study  │
│ (where Incyte can delegate the sponsorship to a preferred CRO if applicable) that is approved to     │
│ enroll into this rollover study is receiving ruxolitinib and has fulfilled all of the requirements   │
│ of the parent protocol                                                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient is currently benefiting from the treatment with ruxolitinib as determined by the             │
│ investigator                                                                                         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient has demonstrated compliance as assessed by the investigator with the parent study protocol   │
│ requirements Willingness and ability to comply with scheduled visits treatment plans and any other   │
│ study procedures                                                                                     │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient currently has no evidence of progressive disease as determined by the investigator following │
│ previous treatment with ruxolitinib                                                                  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Written informed consent obtained prior to enrolling in roll-over study and receiving study          │
│ medication If consent cannot be expressed in writing it must be formally documented and witnessed    │
│ ideally via an independent trusted witness                                                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient has participated in a combination trial where ruxolitinib was dispensed in combination with  │
│ another study medication and the patient is still receiving combination therapy                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Pregnant or nursing (lactating) women where pregnancy is defined as the state of a female after      │
│ conception and until the termination of gestation confirmed by a positive hCG laboratory test        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Women of child-bearing potential defined as all women physiologically capable of becoming pregnant   │
│ unless they are using highly effective methods of contraception throughout the study duration        │
│ inclusive of the 30-day safety follow up                                                             │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Patient currently has no evidence of progressive disease as determined by the investigator following │
│ previous treatment with ruxolitinib or combination of ruxolitinib and panobinostat                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient's indication is currently approved and reimbursed in the corresponding country for           │
│ ruxolitinib monotherapy or combination of ruxolitinib and panobinostat                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 1 Month                                                                     │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Pregnant or nursing (lactating) women                                                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Key                                                                                                  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient is currently benefiting from the treatment with ruxolitinib monotherapy or combination of    │
│ ruxolitinib and panobinostat as determined by the investigator                                       │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient has demonstrated compliance as assessed by the investigator with the parent study protocol   │
│ requirements                                                                                         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient has been permanently discontinued from study treatment in the parent study due to any reason │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient is currently enrolled in a Novartis GDD or GMA-sponsored or Incyte-sponsored clinical study  │
│ are receiving either ruxolitinib or combination of ruxolitinib and panobinostat and fulfilled all of │
│ the requirements of the parent protocol                                                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female patients of childbearing potential (e g are menstruating) who do not agree to abstinence or   │
│ if sexually active do not agree to the use of highly effective contraception throughout the study    │
│ and for up to 30 days after stopping study treatment                                                 │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Other protocol-defined Inclusion / Exclusion criteria may apply                                      │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛